These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 34632802)
1. Nano-carriers of COVID-19 vaccines: the main pillars of efficacy. Constantin C; Pisani A; Bardi G; Neagu M Nanomedicine (Lond); 2021 Nov; 16(26):2377-2387. PubMed ID: 34632802 [TBL] [Abstract][Full Text] [Related]
2. Vaccines against SARS-CoV-2 variants and future pandemics. Park T; Hwang H; Moon S; Kang SG; Song S; Kim YH; Kim H; Ko EJ; Yoon SD; Kang SM; Hwang HS Expert Rev Vaccines; 2022 Oct; 21(10):1363-1376. PubMed ID: 35924678 [TBL] [Abstract][Full Text] [Related]
3. COVID-19 Vaccine: A comprehensive status report. Kaur SP; Gupta V Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805 [TBL] [Abstract][Full Text] [Related]
4. Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. Nel AE; Miller JF ACS Nano; 2021 Apr; 15(4):5793-5818. PubMed ID: 33793189 [TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
7. The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges. Malik JA; Ahmed S; Mir A; Shinde M; Bender O; Alshammari F; Ansari M; Anwar S J Infect Public Health; 2022 Feb; 15(2):228-240. PubMed ID: 35042059 [TBL] [Abstract][Full Text] [Related]
8. The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants. Damasceno DHP; Amaral AA; Silva CA; Simões E Silva AC Curr Med Chem; 2022; 29(15):2673-2690. PubMed ID: 34473613 [TBL] [Abstract][Full Text] [Related]
9. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087 [TBL] [Abstract][Full Text] [Related]
10. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
11. Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential vaccine against SARS-CoV-2. Moshref Javadi M; Taghdisi Hosseinzadeh M; Soleimani N; Rommasi F Microb Pathog; 2022 Sep; 170():105687. PubMed ID: 35917987 [TBL] [Abstract][Full Text] [Related]
12. Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2. Lee KM; Lin SJ; Wu CJ; Kuo RL Biomed J; 2023 Feb; 46(1):70-80. PubMed ID: 36642222 [TBL] [Abstract][Full Text] [Related]
13. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Frederiksen LSF; Zhang Y; Foged C; Thakur A Front Immunol; 2020; 11():1817. PubMed ID: 32793245 [TBL] [Abstract][Full Text] [Related]
14. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines. Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250 [TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. Gong W; Parkkila S; Wu X; Aspatwar A Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216 [TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus. Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668 [TBL] [Abstract][Full Text] [Related]
17. Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based Covid-19 Vaccines: Possible Integration into the Human Genome - Are Adenoviral Genes Expressed in Vector-based Vaccines? Doerfler W Virus Res; 2021 Sep; 302():198466. PubMed ID: 34087261 [TBL] [Abstract][Full Text] [Related]
18. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Pelletier AN; Sekaly RP; Tomalka JA Curr Opin Virol; 2022 Feb; 52():89-101. PubMed ID: 34902803 [TBL] [Abstract][Full Text] [Related]
19. A review of the safety and efficacy of current COVID-19 vaccines. Huang Z; Su Y; Zhang T; Xia N Front Med; 2022 Feb; 16(1):39-55. PubMed ID: 35122210 [TBL] [Abstract][Full Text] [Related]
20. The way of SARS-CoV-2 vaccine development: success and challenges. Dong Y; Dai T; Wang B; Zhang L; Zeng LH; Huang J; Yan H; Zhang L; Zhou F Signal Transduct Target Ther; 2021 Nov; 6(1):387. PubMed ID: 34753918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]